Search Result
Results for "
immunogenic antigen
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-157745
-
|
mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)
|
Liposome
|
Others
|
|
m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
|
-
-
- HY-109506
-
DPPC
3 Publications Verification
129Y83
|
Liposome
Endogenous Metabolite
|
Others
|
|
DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
-
- HY-P1778A
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
|
-
-
- HY-157174
-
|
|
Others
|
Inflammation/Immunology
|
|
Mannosamine-desthiobiotin adduct (compound MDTBA) is a carrier immunogenicity-reducing hapten that reduces the immunogenicity of protein carriers upon conjugation to available free amines on the carrier protein surface. Conjugation of Mannosamine-desthiobiotin adduct to hsIgG significantly (>1-fold) reduced the immunogenicity of hsIgG. Mannosamine-desthiobiotin adduct can be used in antigen design research .
|
-
-
- HY-P1778
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
|
-
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
Liposome
|
Others
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
Liposome
|
Others
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
Liposome
|
Others
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
Liposome
|
Others
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
Liposome
|
Others
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
-
- HY-D1056
-
|
LPS
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Lipopolysaccharides (LPS) is an endotoxin derived from the outer leaflet of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consists of an antigen O-specific chain, a core oligosaccharide and lipid A. Lipopolysaccharides is a pathogenic associated molecular pattern (PAMP) that activates the immune system. Lipopolysaccharides activates TLR-4 on immune cells . This product is derived from Escherichia coli O55:B5. Lipopolysaccharides induces secretion of cell migrasome .
|
-
-
-
HY-L172
-
|
|
80 Compounds compounds
|
|
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.
MCE designs a unique collection of 80 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.
|
| Cat. No. |
Product Name |
Type |
-
- HY-109506
-
DPPC
3 Publications Verification
129Y83
|
Drug Delivery
|
|
DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice .
|
-
- HY-155909
-
|
mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909A
-
|
mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909B
-
|
mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-155909C
-
|
mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-W591424
-
|
mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)
|
Drug Delivery
|
|
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
|
-
- HY-D1056
-
|
LPS
|
Biochemical Assay Reagents
|
|
Lipopolysaccharides (LPS) is an endotoxin derived from the outer leaflet of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consists of an antigen O-specific chain, a core oligosaccharide and lipid A. Lipopolysaccharides is a pathogenic associated molecular pattern (PAMP) that activates the immune system. Lipopolysaccharides activates TLR-4 on immune cells . This product is derived from Escherichia coli O55:B5. Lipopolysaccharides induces secretion of cell migrasome .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1778A
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
|
-
- HY-P1778
-
|
|
HPV
|
Infection
|
|
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
|
-
- HY-P5471
-
|
[Leu27]-Melan-A, MART-1 (26-35)
|
Peptides
|
Others
|
|
Melan-A/MART-1 analog ([Leu27]-Melan-A, MART-1 (26-35)) is a biological active peptide. (This Melan-A (26-35) analog, Leu substituted for Ala at position 27, shows better HLA-A*0201 binding properties as well as better immunogenicity and antigenicity than the natural Melan-A (26-35).Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
